Biotech Patents

The biotech industry faces massive, imminent, change with patent reform nearing passage, impending promulgation of biosimilar pathway regulations from the FDA, the continued evolution of case law from the Federal Circuit and an unusually active Supreme Court. Cases like Therasense, Centocor, McKesson, and Myriad are changing long-standing precedents in inequitable conduct, written description requirements, joint infringement, and the patentability of DNA sequences, and have the potential to signifi cantly alter the biotech patent landscape. Additionally, the FDA’s issuance of biosimilar regulation draws closer. Most signifi cantly, at press time, with both houses of Congress passing versions of patent reform and President Obama signaling he will sign it into law, the patent code is poised to undergo its most sweeping changes in nearly sixty years. The switch to a first-to-file regime, introduction of opposition proceedings, changes to the best mode disclosure requirement and more will challenge biotech patent practitioners like never before. In the most uncertain and anxious period for the biotech industry in a generation, our forum on Biotech Patents will help you develop strategies to confront and conquer these difficulties. Although the biotech world will grapple with shifting case law and the looming alterations in patent code and FDA rules, these changes nevertheless present tremendous opportunities for companies to strengthen patent rights and seize market share. Although this is a challenging period, it is one in which massive growth can be attained and our faculty of experienced counsel will help you chart the best course.

With this in mind, ACI’s 13th Advanced Forum on Biotech Patents brings together another top-notch faculty of expert biotech patent counsel who will share their experience and knowledge to provide you with strategies to navigate this period of intense uncertainty.

Do not miss this opportunity to hear our high quality faculty of senior biotech practitioners share their thoughts and advice on strategic patent fi ling and effective defense of intellectual property rights. Topics to be discussed include:

• Analyzing the potential ramifications of patent reform legislation and the promulgation of biosimilar regulations by the FDA
• Investigating the implications of recent court opinions on the written description requirement, inequitable conduct, joint infringement claims, subject matter patentability, and more
• Formulating strategies for international patent filing in the EU and developing countries

To accompany your overall experience, PTO examiners and industry leaders will guide you through changes to PTO practices in our in depth pre-conference Interactive Working Group Session: Integrating Changes at the PTO into Biotech Patent Practices.

In addition, our Master Class on Successful and Practical Strategies for Patenting Antibodies will utilize an expert faculty to assist you in protecting and promoting products that are central to the biotech industry.

In such uncertain times this industry-leading leading event is sure to sell out, so be sure to reserve your spot today. Register now by calling 888.224.2480; by faxing your registration form to 877.927.1563; or register online at www.AmericanConference.com/BiotechPatents.

Sponsors:

Media Partners:

- Actions -

- Share -